HER-2 protein overexpression
Clinical trials for HER-2 protein overexpression explained in plain language.
Never miss a new study
Get alerted when new HER-2 protein overexpression trials appear
Sign up with your email to follow new studies for HER-2 protein overexpression, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a platform trial match the right drug combo to each tumor?
Disease control Recruiting nowThis phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…
Matched conditions: HER-2 PROTEIN OVEREXPRESSION
Phase 1/2 • Sponsor: QuantumLeap Healthcare Collaborative • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New antibody drug targets HER2 cancers in broad trial
Disease control Recruiting nowThis phase 2 trial tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers, including breast, lung, stomach, and others. Participants have already tried at least one standard treatment. The study measures how many tumors shrink or disappear. Zanida…
Matched conditions: HER-2 PROTEIN OVEREXPRESSION
Phase 2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Engineered immune cells take on sarcoma in new combo trial
Disease control Recruiting nowThis study tests whether a new type of immune cell therapy (HER2-CAR T cells) combined with drugs that boost the immune system (pembrolizumab or nivolumab) is safe for people with advanced sarcoma. About 25 participants will receive chemotherapy before the cell infusion to help t…
Matched conditions: HER-2 PROTEIN OVEREXPRESSION
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC